Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 8/20 | 0.40 |
| ▸ | POLB | P06746 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 4/20 | 0.39 |
| ▸ | HPGD | P15428 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 2/20 | 0.34 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.34 |
| ▸ | PLAU | P00749 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16973600 | 0.91 | L3MBTL1 (0.38) | L3MBTL1POLBMAPTHPGDALDH1A1 | |
| SCHEMBL4532814 | 0.86 | L3MBTL1 (0.40) | L3MBTL1POLBMAPTHPGDALDH1A1 | |
| SCHEMBL4885849 | 0.84 | CSNK2A1 (0.44) | L3MBTL1POLBMAPTHPGDALDH1A1 | |
| SCHEMBL3082367 | 0.83 | FDPS (0.33) | L3MBTL1POLBMAPTHPGDALDH1A1 | |
| SCHEMBL4887608 | 0.83 | L3MBTL1 (0.45) | L3MBTL1POLBMAPTHPGDALDH1A1 | |
| SCHEMBL14814247 | 0.82 | L3MBTL1 (0.39) | L3MBTL1POLBHPGDALDH1A1CYP2C9 | |
| SCHEMBL4888139 | 0.82 | SMN1; SMN2 (0.42) | L3MBTL1MAPTALDH1A1CYP2C9CYP2C19 | |
| SCHEMBL4885840 | 0.81 | HPGD (0.38) | L3MBTL1POLBMAPTHPGDALDH1A1 | |
| SCHEMBL1691562 | 0.81 | MCHR1 (0.40) | L3MBTL1POLBMAPTHPGDALDH1A1 | |
| SCHEMBL27639456 | 0.81 | MAPT (0.38) | L3MBTL1MAPTHPGDALDH1A1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3099685-A1 | NOVEL DIHYDROQUINOLIZINONES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. Hoffmann-La Roche AG (CH) | 2016-12-07 | — | — | EP | disclosed |
| WO-2015113990-A1 | NOVEL DIHYDROQUINOLIZINONES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. HOFFMANN-LA ROCHE AG (CH) | 2015-08-06 | — | — | WO | disclosed |
| US-20080293939-A1 | QUINAZOLINONE DERIVATIVES USEFUL AS ANTI-HYPERALGESIC AGENTS | CULSHAW ANDREW JAMES | 2008-11-27 | — | — | US | disclosed |
| CN-100432059-C | Quinazolinone derivatives useful as anti-hyperalgesic agents | NOVARTIS AG (CH) | 2008-11-12 | — | — | CN | disclosed |
| CN-1711249-A | Quinazolinone derivatives useful as anti-hyperalgesic agents | NOVARTIS AG (CH) | 2005-12-21 | — | — | CN | disclosed |
| WO-2001009087-A1 | SUBSTITUTED ARYLHYDRAZONE CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS HERBICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 2001-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293939-A1 | QUINAZOLINONE DERIVATIVES USEFUL AS ANTI-HYPERALGESIC AGENTS | OPRK1, OPRL1, TRPV1 | L3MBTL1 2929/4885POLB 4574/4885MAPT 4614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.